Histone deacetylase inhibitors as a new anticancer option: How far can we go with expectations?

被引：0

作者：

Garmpi, Anna ^{[1
]}

Garmpis, Nikolaos ^{[2
,3
]}

Damaskos, Christos ^{[2
,3
]}

Valsami, Serena ^{[4
]}

Spartalis, Eleftherios ^{[3
]}

Lavaris, Anastasios ^{[5
]}

Patelis, Nikolaos ^{[6
]}

Margonis, Georgios-Antonios ^{[7
]}

Apostolou, Konstantinos G. ^{[8
]}

Spartalis, Michael ^{[9
]}

Andreatos, Nikolaos ^{[7
]}

Diamantis, Evangelos ^{[2
]}

Tsivelekas, Konstantinos ^{[2
]}

Moschos, Marilita M. ^{[5
]}

Nonni, Afroditi ^{[10
]}

Tsourouflis, Gerasimos ^{[2
]}

Markatos, Konstantinos ^{[11
]}

Antoniou, Efstathios A. ^{[2
]}

Kontzoglou, Konstantinos ^{[2
]}

Nikiteas, Nikolaos ^{[3
]}

Dimitroulis, Dimitrios ^{[2
]}

机构：

[1] Univ Athens, Laiko Gen Hosp, Med Sch, Internal Med Dept, Athens, Greece

[2] Univ Athens, Laiko Gen Hosp, Med Sch, Dept Propedeut Surg 2, Athens, Greece

[3] Univ Athens, Med Sch, NS Christeas Lab Expt Surg & Surg Res, Athens, Greece

[4] Univ Athens, Aretaieion Hosp, Med Sch, Blood Transfus Dept, Athens, Greece

[5] Univ Athens, Gen Hosp Athens G Gennimatas, Dept Ophthalmol 1, Athens, Greece

[6] Univ Athens, Laiko Gen Hosp, Med Sch, Dept Surg 1,Vasc Unit, Athens, Greece

[7] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA

[8] Univ Athens, Laiko Gen Hosp, Med Sch, Dept Surg 1, Athens, Greece

[9] Onassis Cardiac Surg Ctr, Div Cardiol, Athens, Greece

[10] Univ Athens, Sch Med, Dept Pathol 1, Athens, Greece

[11] Acad Athens, Biomed Res Fdn IIBEA, Athens, Greece

来源：

JOURNAL OF BUON | 2018年 / 23卷 / 04期

关键词：

cancer; deacetylase; epigenetics; Histone; targeted; inhibitor; SUBEROYLANILIDE HYDROXAMIC ACID; PANCREATIC-CANCER CELLS; TRICHOSTATIN-A; PHASE-I; SYNERGISTIC ACTIVITY; HDAC INHIBITORS; GENE-EXPRESSION; NUCLEAR EXPORT; LEUKEMIA-CELLS; RETINOIC ACID;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Histone modification that occurs through the process of acetylation plays a key role in the epigenetic regulation of gene expression. The balance between histone deacetylases (HDACs) and histone acetyltransferases controls this process. Histone deacetylase inhibitors (HDACIs) can induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response. Therefore, HDAIs represent a group of enzymes that can be used for the development of pharmaceutical agents against a variety of malignant diseases. The mechanisms of their anticancer effect depend on many factors. HDACIs vorinostat, romidepsin and belinostat have been approved for some T-cell lymphomas and panobinostat for multiple myeloma. Other HDACIs are tested in clinical trials for the treatment of hematological and solid malignancies. The results of such studies are promising but further larger studies are needed.

引用

页码：846 / 861

页数：16

共 150 条

[1] HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination [J].

Adimoolam, Shanthi ;

Sirisawad, Mint ;

Chen, Jun ;

Thiemann, Patti ;

Ford, James M. ;

Buggy, Joseph J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (49) :19482-19487

[2] NuRD and SIN3 - histone deacetylase complexes in development [J].

Ahringer, J .

TRENDS IN GENETICS, 2000, 16 (08) :351-356

[3] Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer [J].

Alzoubi, Samer ;

Brody, Leigh ;

Rahman, Sunniyat ;

Mahul-Mellier, Anne-Laure ;

Mercado, Nicolas ;

Ito, Kazuhiro ;

El-Bahrawy, Mona ;

Silver, Andrew ;

Boobis, Alan ;

Bell, Jimmy D. ;

Hajji, Nabil .

ONCOTARGET, 2016, 7 (28) :44505-44521

[4] The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer [J].

Arnold, Nichole Boyer ;

Arkus, Nolhea ;

Gunn, Jason ;

Korc, Murray .

CLINICAL CANCER RESEARCH, 2007, 13 (01) :18-26

[5] Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors [J].

Bali, P ;

Pranpat, M ;

Bradner, J ;

Balasis, M ;

Fiskus, W ;

Guo, F ;

Rocha, K ;

Kumaraswamy, S ;

Boyapalle, S ;

Atadja, P ;

Seto, E ;

Bhalla, K .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (29) :26729-26734

[6] SIK1 is a class IIHDAC kinase that promotes survival of skeletal myocytes [J].

Berdeaux, Rebecca ;

Goebel, Naomi ;

Banaszynski, Laura ;

Takemori, Hiroshi ;

Wandless, Thomas ;

Shelton, G. Diane ;

Montminy, Marc .

NATURE MEDICINE, 2007, 13 (05) :597-603

[7] Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation [J].

Borbone, E. ;

Berlingieri, M. T. ;

De Bellis, F. ;

Nebbioso, A. ;

Chiappetta, G. ;

Mai, A. ;

Altucci, L. ;

Fusco, A. .

ONCOGENE, 2010, 29 (01) :105-116

[8]

Bosch-Presegue Laia, 2011, Genes Cancer, V2, P648, DOI 10.1177/1947601911417862

[9] HDAC6-p97/VCP controlled polyubiquitin chain turnover [J].

Boyault, Cyril ;

Gilquin, Benoit ;

Zhang, Yu ;

Rybin, Vladimir ;

Garman, Elspeth ;

Meyer-Klaucke, Wolfram ;

Matthias, Patrick ;

Muller, Christoph W. ;

Khochbin, Saadi .

EMBO JOURNAL, 2006, 25 (14) :3357-3366

[10] The Notch signaling pathway is related to neurovascular progression of pancreatic cancer [J].

Büchler, P ;

Gazdhar, A ;

Schubert, M ;

Giese, N ;

Reber, HA ;

Hines, OJ ;

Giese, T ;

Ceyhan, GO ;

Müller, M ;

Büchler, MW ;

Friess, H .

ANNALS OF SURGERY, 2005, 242 (06) :791-801

← 1 2 3 4 5 6 7 8 9 10 →